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SUMMARY
Excessive exposure of skin to ultraviolet radiation (UVR) has dramatic clinical effects in
humans, and it is a significant public health concern. Discomfort and sensory changes
caused by skin sunburn are the main common features experienced by many of us, a phe-
nomena triggered by the combination of long and short wavelengths radiation (UVA and
UVB, respectively). Although the biological processes underlying UVR exposure are not
fully understood, in the last few years many studies have made significant progress in char-
acterizing sunburn at the cellular and molecular levels, making use of both humans and lab-
oratory animal models. Here we review and reason that UVR can be used as an excellent
model of sensitization and inflammation for pain research. UVR, particularly UVB, produces
a controllable and sterile inflammation that causes a robust dose-dependent hypersensitiv-
ity with minimal confounding effects. Importantly, we show that UVR animal models pre-
cisely recapitulate the sensory, cellular, and molecular changes observed in human skin,
giving it great confidence as a translational model. Furthermore, in this article, we give an
overview of the pharmacology underlying UVB inflammation, the latest advances in the
field, and potential new targets for inflammatory pain.
Introduction
Excessive exposure of the skin to ultraviolet radiation (UVR) is a
common occurrence in tropical and even temperate latitudes. The
result, sunburn, is well known to most of us. In extreme cases, this
reaction can be life-threatening [1,2], but in most cases, it results
in only a few days of discomfort. However, the sensory features of
sunburn, which we review in this chapter, make this a very inter-
esting experimental model to study, in a controllable way, fea-
tures of the pain-signaling system that are relevant to many forms
of chronic pain. Specifically, we will argue that UVR can be used
to selectively study the process of peripheral sensitization of noci-
ceptors, with minimal confounding effects of any central sensory
changes.
Recent epidemiological studies have demonstrated that sun-
burn is experienced by a large proportion of the population, affect-
ing almost 75% of adolescents and young adults in the USA, and
over 50% of the same age group in northern European countries
[3–7]. Despite its high prevalence, the understanding of the cellu-
lar processes underling the damages caused by UVR exposure
remains limited, as are the treatments available to overcome the
sensory changes associated with it. Developing and validating
models to understand the biological processes implicated in sun-
burn offers the opportunity for improving our understanding of
pain mechanisms. Most importantly, we reason in this review that
UVR can be used as a model of inflammatory pain for a broad
spectrum of studies in pain research in both humans and in labo-
ratory animals.
Consequences of UVR on Skin
Acute exposure to UVR triggers several changes in the skin. These
include hyperemia, hyperalgesia, and inflammation, and all can
result from exposure to different UV wavelengths. Notably, con-
siderable evidence suggests that long-wave UVA, which pene-
trates to the deeper layers of the dermis, has a relatively milder
impact on the skin than short-wave UVB irradiation, which is
mainly absorbed by the epidermis [8]. Histopathological studies
dating back to the late 1970s tried to understand in more detail
the effect of UVR on the skin. They revealed that UVA is more
detrimental to deeper layers of the skin than UVB, affecting
mainly capillaries by inducing degeneration of endothelial cells
[9–11]; however, this difference is to some extent dose-depen-
dent. Increasing the energy of the UVA irradiation also induces
skin erythema [11,12], but it is likely that cellular responses are
distinct for differing wavelengths of UVR [9–11]. Following these
findings, a study evaluating hyperalgesia and erythema following
UVA exposure suggested there are no major alterations in thermal
or mechanical algesia either 1 or 24 h postirradiation [8]. Further-
more, although UVA irradiation is sufficient to produce tanning of
the skin, changes in erythema and skin temperature in the areas
exposed to UVA were only observed for a few hours after expo-
sure [8,13]. Although the authors concluded that UVA produced
very limited hyperalgesia, very low doses of UVA (16.8 and
36 mJ/cm2) were used in these studies. A more recent study,
however, comparing solar simulated radiation to UVA at similar
erythema doses, the minimal UV dose sufficient to cause acute
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redness of the skin, demonstrated that both types of radiation pro-
duced similar skin sensitization [14]. Additionally, a time course
analyses demonstrated that 24 h after exposure a substantial
increase in sensitivity to mechanical and heat pain was observed
in the UVA irradiated area [14]. Notably, the authors emphasized
that the UVA doses used in the study (on average 56.5 mJ/cm2)
are higher than those obtained from sunlight, which accounts for
a minimal part of the solar radiation (approximately 10%) [14].
Nonetheless, the study demonstrates that UVA can produce ery-
thema, which is accompanied by tenderness of the skin and
hyperalgesia, which peaks at 24 h postirradiation [14]. At the
opposite end of the spectrum sits UVC radiation, which, interest-
ingly, has virtually no contribution to sunburn-associated skin
damage, as most of it is absorbed by the ozone layer and does not
reach the Earth’s surface [15–17]. Together, these studies indi-
cated that UVA does indeed induce skin changes; while UVA,
UVB, and UVC can all induce erythema and sensory changes, the
relative efficiencies of each of the wavelengths in causing damage
and their abundance in solar radiation reaching the Earth’s sur-
face mean that UVB is responsible for most of the sunburn that
humans naturally experience.
It is well established that UV light in the UVB range is absorbed
by the epidermis, leading to changes in its structure, and ulti-
mately triggering cellular toxicity in the damaged region [11,12].
UVB irradiation leads to a range of intracellular changes, including
DNA damage, changes in gene expression, increased levels of reac-
tive oxygen species, and a significant inflammatory response at
the injury site [18–22]. More importantly, this phenomenon is
accompanied by erythema and increased cutaneous hypersensitiv-
ity to mechanical and thermal stimuli (Figure 1A and B) [8,13,23–
25]. Furthermore, inflammation and hypersensitivity is reported
to show both dose and time-dependence peaking 24 to 48 h after
the UV insult (Figure 1B) [8,23]. When comparing skin exposed
to different spectra of UV, many studies have demonstrated that
skin is most sensitive to UVB wavelengths and that these are most
likely responsible for the erythema and altered sensory changes
observed at the exposed area [8,14,23]. An important characteris-
tic of UVB is that it produces very similar changes in the skin of
many mammals; in particular, sensory changes are similar in
human, rat, and mouse skin (Figure 1C). This, as we will discuss,
has led to its use as a translational model for the study of pain.
Wavelength is one variable that changes the ability of UVR to
induce erythema and hyperalgesia in skin. Another variable is the
pigmentation of skin, which, of course, can vary dramatically
between individuals. For this reason, when UVR is administered
to humans, it is usually “calibrated” in terms of its efficacy. The
standard measure is MED or minimal erythemic dose; this is the
amount of UVB, of any wavelength or mixture of wavelengths,
that produces in an individual a clear area of erythema with dis-
tinct edges, as assessed 24 h after irradiation. Because laboratory
animals are more homogeneous in their responsiveness to UVR,
experimental studies that utilize animals often define the UV dose
in terms of energy of irradiation.
UVB elicits sensitization of nociceptors. The skin is richly inner-
vated by highly specialized sensory fibers that provide information
to the CNS about the environment and integrity of the tissue
[26,27]. Sensory receptors innervating the skin have been exten-
sively studied. These fibers can be classified in many ways, but
most traditionally by size, where three types of fibers are recog-
nized: large myelinated Ab, small myelinated Ad, and unmyeli-
nated C fibers, each with a differential but overlapping sensitivity
to applied stimuli [27–30]. However, we can generalize (at the risk
of oversimplifying) to say that Ab fibers mostly respond to innocu-
ous mechanical stimulation, whereas Ad encode some forms of
nociceptive stimuli as well as cold stimuli, C fibers can respond to
noxious, warm, or innocuous mechanical stimuli [27–30]. The
specific role of different classes of afferent fiber remains an area of
active ongoing research. For our purposes here, the majority of Ad
and C fibers are nociceptive and we are interested in how UVR
affects their responsiveness.
Chronic UVR exposure can have effects beyond nociceptor sen-
sitization. It is clear that sunlight is an essential part of human life,
for example, it is required for the production of vitamin D; how-
ever, mounting evidence suggests there are long-term damaging
(A) (C)
(B) (D)
Figure 1 Features of UVB-induced inflammation.
(A) Cutaneous UVB exposure produces dose-
dependent erythema. From left to right patches
of skin were exposed to 1, 2, and 3 MED on the
volar aspect of the forearm 24 h previously.
(B) Time course of UVB-induced mechanical
hyperalgesia in human volunteers. The white
line shows sensitivity of a control site, while the
red, yellow, and blue lines show changes after
1, 2, and 3 MED exposure, respectively. (C)
Erythema in rat paw, 24 h after exposure of
500 mJ/cm2. (D) UVB-induced mechanical
hypersensitivity in rats, before and after
exposure to 0 (white line), 250 mJ/cm2 (red),
500 mJ/cm2 (yellow), and 1000 mJ/cm2 (blue).
These doses are roughly equivalent to 1, 2, and
4 MED.
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consequences to the skin. Regular exposure to solar radiation can
lead to the development of deep wrinkles, leathery skin, dark
spots, and dilatation of superficial blood vessels, collectively a pro-
cess known as photoaging [31–33]. Further to the cosmetic
changes to the skin, an overwhelming number of scientific studies
and epidemiological analyses have demonstrated that chronic
exposure to the UV component of sunlight can lead to melanoma
and nonmelanoma skin cancers [34,35]. Interestingly, more
recent studies suggest that intermittent burning doses of UV dur-
ing childhood are a major risk factor to develop skin cancer later
in life [34,36,37]. In addition, and contributing to its carcinogenic
potential, chronic exposure to UV radiation can alter immune
responses [38–40]; this occurs via direct modulation of the
immune system, creating a net imbalance toward immunosup-
pression [38–40]. Although it is believed that UV-induced
immunosuppression is a transient protective process used by cells
to repair and maintain genomic integrity, studies have indicated
that there is a clear association between the immune suppressive
effects of UV and its carcinogenic effect [40]. It should be noted,
however, that photoaging and cancer are consequences of long-
term and repetitive exposure to UV solar radiation, rather than a
distinct feature of acute pain and hyperalgesia that is the focus of
this review.
UVB and Pain in Rodents: A Reliable
Model
The importance of validating models that accurately reflect
human diseases and/or conditions is a challenge in science.
Although UVB-induced hyperalgesia has been investigated in dif-
ferent species, from flies to humans [8,14,41], rodents are of
course a particularly important preclinical model system. Aiming
to study the consequences of UVB in rodents, Saade et al. irradi-
ated the skin located over the back region of mice and observed a
dramatic inflammatory response and changes in thermal sensitiv-
ity as consequence of UVB insult [42]. Interestingly, these authors
also showed a direct correlation between the UVB dose and
decrease in the thermal sensitivity [42]. Several subsequent stud-
ies confirmed the basic findings. Furthermore, following the work
by Saade et al., there is a general consensus as to the time course
of hyperalgesia: in most studies, it peaks between 24 and 48 h,
after which the sensory changes slowly abate.
Just as in humans, local mechanical sensitization is observed in
rodents exposed to UVB. One key study looked in greater detail at
the skin damage observed upon acute exposure to UVR and suc-
cessfully developed a model that reflects UVB-induced inflamma-
tion and hypersensitization observed in humans [24]. The study
evaluated the plantar hind paw skin of rats exposed to different
doses of UVB and demonstrated that increased thermal sensitiza-
tion was induced in a dose-dependent manner [24]. Indeed, the
authors showed that a single acute exposure of a 250 mJ/cm2 dose
is sufficient to produce erythema and increased blood flow in the
irradiated area [24]. The range of doses evaluated in the study was
sufficient to induce an increase in hind paw blood flow of up to
500%, together with a dramatic decrease in thermal pain thresh-
old [24]. Of equal importance, the study demonstrated a signifi-
cant decrease (up to 80%) in the mechanical pain threshold in the
area exposed to UVB (Figure 1D) [24]. Interestingly, time course
observations revealed sensory changes peaked 24 to 48 h postirra-
diation and coincided with the peak of erythema (Figure 1D)
[24]. Adding to these findings, Saade and collaborators further
characterized this UVB model, by analyzing the skin at protein
and cytokines levels, they revealed that inflammatory response
occurs concomitantly with hypersensitivity [43]. Consistent with
previous observations, the decrease in pain thresholds triggered
by UVB inflammation was reduced 72 h after exposure [24,43].
Additionally, sensitization triggered by UVR was restricted to the
exposed paw only [43]. Together, these key studies successfully
developed a unique model that helped with the understanding of
UVB-mediated pain, as discussed below.
What is the Mechanism of Hyperalgesia
in UVB Irradiation: Peripheral and
Central Sensitization?
It is well recognized that sensitization of the pain-signaling system
can arise at peripheral terminals (peripheral sensitization) or in
the CNS, best studied in the spinal cord (central sensitization).
Given the two distinct forms of alteration of pain processing, an
obvious question is: What mechanism underlies UVR hyperalge-
sia? It is accepted that in some types of tissue trauma, increased
sensitivity can also be seen in the tissues surrounding the injured
area, a phenomenon believed to be a consequence of changes in
neuronal excitability, particularly at the level of the spinal cord
[44–47].
Whether UVB injury induces changes in synaptic plasticity in
the CNS is still a subject of debate in the pain field. Several lines of
evidence from studies in humans demonstrate that increased
mechanical and thermal sensitivity as a consequence of UVR dam-
age is restricted to the site of irradiation and does not lead to cen-
tral sensitization [14]. Adding to this argument are data from a
study directly comparing UVB inflammation to two other tradi-
tional models of hyperalgesia in human skin [23]. Here, the
authors demonstrated that whereas thermal burn and topical cap-
saicin produce both primary and secondary hypersensitivity
(demonstrated by pin prick hyperalgesia and allodynia in adjacent
areas of the lesion), in the UVB model skin sensitization is
restricted to the inflamed area, without evoking changes in central
pain processing [23]; a similar conclusion has been reached by
other research groups [48–50]. One of these studies reports no
changes in sensitization to heat, sharpness, or pressure at the sec-
ondary areas tested, indicating there had been no induction of
central mechanisms underlying the UVB burn [50]. Together,
these studies suggest that peripheral sensitization is the predomi-
nant mechanism underlying UVB-induced hyperalgesia in
humans. However, there is some conflicting literature which we
discuss later in the article.
Peripheral sensitization appears to be prominent in animal
models of UVB irradiation. Although the first proposed animal
model of UVB suggested that nonirradiated areas might be
affected by UVR [42], perhaps due to the uncontrolled extent of
the area damaged [42], Bishop and collaborators make a strong
argument that UVB leads to a predominant peripheral sensitiza-
tion [24]. This study suggested that irradiation does not produce
any spontaneous pain behavior in the area irradiated, such as
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flinching, licking, or paw lifting [24]. More importantly, the group
reports no induction of c-fos immunoreactivity in the spinal cord
of rats with irradiated hind paws compared to a sham irradiated
group [24]. The group did demonstrate that UVB irradiation can
facilitate noxious-evoked c-fos expression at the spinal cord level,
corresponding to the area irradiated, but attributed this to periph-
eral sensitization as there was no induction of c-fos after UVB
without noxious stimulation [24]. Furthermore, it is well estab-
lished that central sensitization is heavily dependent on recruit-
ment of NMDA receptors [51–53], and it has been shown that
UVB-mediated mechanical hypersensitivity is not reduced by
pharmacological blockade of spinal NMDA receptors [24]. These
experiments, together with other studies [43], provide strong evi-
dence for an absence of spontaneous or ongoing pain induced by
UVB, as is the experience of most people with sunburn. Further-
more, these findings set this model apart from other established
models of inflammation, such as CFA and carrageenan, where
central sensitization is clearly documented [53–55].
However, there are other somewhat conflicting studies. The first
evidence suggesting that UVB induces sensitization in skin areas
adjacent to inflammation comes from human studies [56]. By
evaluating the responses to different stimuli, the authors reported
the occurrence of large areas of secondary pinprick hyperalgesia
with increased sensitivity stable during a 10-h follow-up period
after the first test [56]. Notably, no differences in the heat and
electrical pain tolerances were found at the secondary areas [56].
In addition, a more recent study by the same authors reported
only a small rim of dynamic mechanical hyperalgesia surrounding
the sunburn area [57]. Following these observations, studies from
the same group reinforced the occurrence of central sensitization
and proposed the use of different drugs to reduce the secondary
mechanical hyperalgesia as result of UVB lesion [56,58–61]. In
these studies, relatively large areas of the skin were UVB-burnt
and were tested repeatedly with suprathreshold stimulation
(which might itself induce central sensitization). These features
may have induced spontaneous activity in nociceptors and can
therefore explain the presence of central sensitization. Hence, dif-
ferences in methodology may explain the contrasting results with
the literature discussed previously.
Can UVB-induced secondary hypersensitization be reproduced
in animal models? Following the above observations in humans
subjected to UVB burn, animal models of UVB-induced hypersen-
sitivity have also been investigated in the context of secondary
sensitization [62,63]. Using the UVB rat model, Davies and col-
leagues proposed that, after injury, the area adjacent to the irradi-
ation becomes sensitive to brush and punctate stimuli [62],
although no changes in the threshold were observed on the side
contralateral to the irradiation [62]. The same study also investi-
gated whether secondary hyperalgesia could be enhanced by the
heat rekindling model, where a strong thermal stimulation is
applied at the UVB-irradiated area for a given period of time [62].
Using this protocol, the authors reported that they can readily
induce central sensitization in areas adjacent to the UVB burn, but
this is then extended to the side contralateral to that irradiated
[62]. Furthermore, enhanced secondary skin hyperalgesia and
allodynia were reported to be a long lasting event, continuing for
up to 10 days after the insult [62]. More recently, using an identi-
cal UVB+ heat rekindling model in combination with pharmaco-
logical manipulations, the same group replicated their findings,
suggesting the occurrence of central sensitization and proposing
the UVB+ heat rekindling as a translational model for inflamma-
tory pain [63]. It is difficult, however, to reconcile all these stud-
ies, as it appears that some paradigms promote primarily
peripheral sensitization while others can also induce central
changes.
UVB-Induced Hypersensitivity:
Pharmacology
The pharmacological sensitivity of the UVR-induced sensory
changes is of interest in defining the utility of the model. Given
the well-acknowledged inflammatory changes and secretion of a
great number of inflammatory mediators as a consequence to
UVB exposure [18,19,42], it is not surprising that several studies
have examined the effects of steroids on sunburn (Table 1). One
of the first double-blind controlled trials evaluating the effects of
antiinflammatory drugs in patients demonstrated that oral admin-
istration of prednisone, either before or after UVB irradiation, does
not decrease redness, edema or tenderness of the affected site
[64]. Since this first report, controlled trials have multiplied and
similar drugs have been tested via systemic administration; how-
ever, they have had little apparent benefit to the subjects. For
instance, a recent study demonstrated that 4 consecutive days of
oral corticosteroid do not have any effect on erythema of irradi-
ated skin [65]. These studies provide clear evidence that systemic
use of corticosteroids is not an effective treatment to alleviate the
symptoms of skin sunburn.
Despite the negative results provided by studies using oral corti-
costeroids, other work suggests that topical application of steroids
can be more effective (Table 1). Evidence from almost 50 years
ago suggests a decrease in the discomfort of severe sunburn when
aerosol corticosteroids were regularly applied in the affected area
after UV overexposure [66]. Following these observations,
another study evaluated the effects of a variety of topical drugs
applied to the skin of subjects exposed to UVB [67]. The authors
report that only potent corticosteroids were efficient in reducing
erythema when applied after irradiation [67], with less convincing
results when the skin was pretreated with antiinflammatory
creams [67]. Nevertheless, more positive outcomes with steroid
creams after UVB sunburn were shown by further studies, which
demonstrated a significant reduction of erythema and blood flow
in irradiated skin treated with topical steroidal cream [68] or solu-
tions [69]. Furthermore, using a more refined method to evaluate
skin damage after UVB exposure followed by topical application of
steroid creams, an elegant study analyzed darker skin that was
subject to different doses of UVB [70]. The results confirmed the
efficiency of corticosteroid in the alleviation of the erythema
experienced, and interestingly, the authors demonstrated the sup-
pression of pigmentation in the treated area [70]. These authors
reported a clear correlation between the degree of erythema and
pigmentation, both of which could be suppressed if corticosteroid
creams were applied immediately after UVB exposure [70].
Regrettably, none of the cited studies evaluated any specific
changes in the mechanical and heat threshold on the trial groups
after the treatment presented above. However, it can be reasoned
that use of topical corticosteroids is beneficial to alleviate UVB-
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Table 1 Summary of pharmacological interventions that have been tested in UVB models
Drug Dose/Time Via Model Outcome Refs.
Corticosteroid
Prednisone 80 mg (pre, during,
and/or after irradiation)
Oral Humans No apparent benefit [64]
Prednisone 30 mg for 4 days Oral Humans No change in threshold
erythema response
[65]
Dichlorisone,
prednilosone
 dexamethasone
or prednisone
Up to 5 mg, regularly
to up to 4 days
Topical  Oral Humans Variable effect, topical
administration just as efficient
as when used in combination
with oral dosages
[66]
Hydrocortisone
and other potent
corticosteroid creams
Before and/or 1 and
4 h postirradiation
Topical Humans Hydrocortisone had no effect
(unless applied before irradiation),
whereas potent corticosteroids
decreased erythema
[67]
Clobetasol propionate
and hydrocortisone
Immediately after irradiation Topical Humans Decreased erythema and pigmentation [70]
Betamethasone
dipropionate
Immediately after irradiation Topical Humans Considerable reduction in erythema
and blood flow from 24 h to 96 h
[68]
Methylprednisolone
acetonate milk or
hydrocortisone
0.1% solution, twice daily,
during 7 days, starting
6 h after irradiation
Topical Humans Both drugs efficaciously reduced
erythema, itch, and pain scores
[69]
Nonsteroidal anti inflammatory drugs (NSAID)
Ibuprofen or k-opioid
receptor agonist
600 mg and 7.5 mg,
respectively, single dose
Oral Humans Ibuprofen significantly reduced
mechanical and heat hyperalgesia;
k-opioid had no apparent benefit
[13]
Ibuprofen Single 800 mg dose,
22 h after irradiation
Oral Humans Ibuprofen significantly reduced
mechanical and heat hyperalgesia
as well as pain tolerance
[71]
Ibuprofen Single 600 mg dose Oral Humans Reduced erythema and heat pain
threshold, with no much change
in skin temperature
[72]
Remifentanil and/or
gabapentin
Singles 0.08 ug/kg
Remifentanil and/or
600 mg gabapentin doses
Oral Humans Remarkable effect of remifentanil
(increased almost 90% heat
pain tolerance threshold),
whereas gabapentin did
not show any positive effect
[56]
Rofecoxib (Cox-2
selective inhibitor)
50, 250, or 500 mg,
24 h after irradiation
Oral Humans Reduction in heat pain perception
and tolerance, as well as in
secondary hyperalgesia
[61]
Ketorolac 2 mg Intrathecal Humans Reduced areas of allodynia,
when UVB was combined to
HR and data analysed in a
special manner
[49]
Indomethacin 2.5% solution, immediately
after the exposure
Topical Reduced skin temperature
and hyperalgesia in the
area exposed; no benefits
of extra application
[73]
Indomethacin 1% cream, immediately
after irradiation
Topical Humans Reduced erythema [70]
Ibuprofen Single, 50, 100,
200 mg/kg; or 0.215 g
Injected
or topical gel
Humans and
guinea-pigs
Considerable reduction in
thermal hyperalgesia
and mechanical allodynia
[24]
Diclofenac 0.1% to 1%, gel Topical Humans Effective on pain and burning
sensation, reduced erythema,
oedema, and skin temperature.
Second application prolonged
the beneficial effects of the drug.
[74]
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triggered pain while systemic corticosteroids are less so, presum-
ably because of limitations in dosing.
UVB-induced hypersensitivity can be alleviated by nonsteroidal
antiinflammatory drugs (NSAID). A number of studies demon-
strate the efficacy of systemic NSAID in reducing skin hyperalgesia
to different stimuli [13,24,61,71] (Table 1). For instance, it has
been reported that single dose of ibuprofen can dramatically
reduce the mechanical and heat sensitivity in the irradiated area
[13]. This analgesic effect of ibuprofen has been further validated
by other studies [71,72], which also reported a significant increase
in pain tolerance in subjects treated with the drug [71]. Following
this trend, other NSAIDs also appear to be equally effective for
treating sunburn when administered systemically [24,56,61]. In
contrast to these findings, however, another study demonstrated
that intrathecal delivery of a NSAID can reduce areas of allodynia
when UVB irradiation is combined with heat stimulus, but has lit-
tle effect on UVB-mediated burns alone [49]. This further suggests
that peripheral effects of NSAIDs in UVR account for most, if not
all, of their beneficial effects. Thus, studies support that local
NSAID can be effective in alleviating UVB-induced sunburn. Fol-
lowing previous observations as to successful effect of NSAID
when applied locally to the affected area [70,73], four decades
later a study comparing the effects of ibuprofen when delivered
systemically or topically, revealed that both treatment methods
equally attenuate hypersensitive and allodynia [24]. Adding to
these observations, other studies not only confirmed the benefits
of local application of NSAID on UVB burns [74], but also sug-
gested no additional advantage in delivering the drug systemically.
Other analgesic drugs have beneficial effects in alleviating the
effects of UVB-induced sunburn. For instance, opioids, a major
class and one of the most powerful analgesic drugs [75–77], can
efficiently reduce the sensory abnormalities triggered by UVB,
whether delivered systemically or locally [24,48,78] (Table 1).
However, some conflicting results have been reported regarding
opioids efficacy [79], perhaps because of suboptimal dosing.
In addition to these traditional analgesic agents, a number of
other drug classes have been evaluated in UVR. One example is the
nerve growth factor (NGF). Given the well-established role of NGF
in inflammatory pain [80–82] and that UVR-exposed skin releases
NGF [42,83–85], it would be reasonable to think that targetingNGF
could be an effective method to reduce UVB-mediated pain.
Indeed, based on this idea, Bishop and collaborators demonstrated
that by sequestering NGF, a modest but significant reduction in the
magnitude of UVB-induced sensory changes could be observed
[24]. Yet, regarding the pro-hyperalgesic mechanism related to
NGF, much evidence suggests that acute NGF stimulation leads to
enhanced responsiveness of TRPV1 receptors [82,86]. Therefore,
selective targeting of TRPV1 receptors might also be an effective
approach to blocking UVB-induced inflammatory pain, and some
work supports this idea. Chizh and colleagues reported that TRPV1
antagonists can modestly reduce both hypersensitivity and
flare area resulting from UVB inflammation [87]. Further to these
observations, amore recent study confirmed the therapeutic effects
of TRPV1 antagonists, demonstrating the antinociceptive and anti-
hyperalgesic effects of a new selective drug to these vanilloid chan-
nels [88]. Adding to the role of TRPV receptor family in UVB-
Table 1 (Continued)
Drug Dose/Time Via Model Outcome Refs.
Opioids
Morphine or loperamide Single dose, 1, 2, and 4 mg/kg Injected Humans Reduction in thermal hyperalgesia
and mechanical allodynia
[25]
Morphine or buprenorphine Single doses, from 0.1 to 0.4% Topical
application
Humans No effect on inflamed skin [79]
Buprenorphine or fentanyl Transdermal patches at
20 ug/h (for 144 h)
and 25 ug/h (for 72 h),
respectively
Local dermal
patches
Humans Buprenorphine, but not fentanyl,
showed analgesic effects
against pain. Adverse
effects were reported.
[48]
Morphine or oxycodone Single dose, 20 to 40 mg
and 10 to 20 mg,
respectively—immediately
after irradiation
Oral Humans Both drugs showed a rapid
and sustained antinociceptive
and analgesic effect,
particularly at the higher doses
[78]
Alterative targets
NGF sequestering
(TrkAd5 molecule)
Single dose, 2 mg/kg,
subcutaneously, at the
time of the inflammation
Injected Rodents Attenuation of thermal
and mechanical hypersensitivity
[24]
TRPV1 antagonist SB-705498 Single dose, 400 mg
postirradiation
Oral Humans Increased heat pain tolerance
and reduced flare area at the
inflamed site. Some
collateral effects were reported
[87]
TRPV1 antagonist ABT-102 Single dose, 0.5, 2, and 6 mg,
postirradiation
Oral Humans Reduced evoked pain at
2 and 6 mg doses
[88]
TRPV4 antagonist GSK205 Single application, 1 to 5 mM,
pre-irradiation
Local Rodents At the highest dose, there was
an increase in the thermal threshold
and striking elimination of tissue damage
[89]
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hypersensitivity, another study claimed that UVB induces expres-
sion of TRPV4 channels at the epidermis, eliciting a proalgesic effect
[89]. Interestingly, UVB-mediated skin damage and hypersensitiv-
ity were attenuated in TRPV4 KO mice and those pretreated with
TRPV4 antagonist [89]. Given that TRPV4 is abundantly expressed
in keratinocytes and other epithelial cells [90–93], the authors
emphasized the role of this subfamily of epidermal cation channel
as a proalgesic mediator of pain [89]. Together, these studies have
demonstrated that by understanding mechanisms underlying UVB
hyperalgesia and sensory changes during inflammation, new ther-
apeutic approaches to treat inflammatory pain states in general can
be developed. Further to the targets above discussed, new exciting
strategies could be developed by the identification of cellular
mechanisms triggered by pain, as discussed below.
Changes in mRNA Transcription and
Protein Levels after UVB Burn: New
Potential Therapeutic Targets
Although the underlying mechanism of UVB-mediated hypersen-
sitivity is not entirely understood, much evidence suggests that
the major component of sensitization lies on the afferent terminals
at the skin [25,94]. Therefore, this model may allow us to identify
novel mediators of sensitization that are important in the UVR
and other pain states. Aiming to identify possible peripheral medi-
ators of hyperalgesia in response to UVB burn, Dawes and collabo-
rators took advantage of developments in “omics” to analyze an
array of 90 different inflammatory mediator candidates in the skin
of rats and humans that were subjected to UVB insult [94]. A large
number of upregulated transcripts were identified by the group,
among them a variety of interleukins, chemokines, and cyclooxy-
genase and iNOS that were consistent between humans and rats
[94]. Notably, a dramatic upregulation of CXCL5 expression was
observed at the peak of inflammation [94]. Moreover, the authors
demonstrated that injection of CXCL5 is proalgesic, producing a
reduction of mechanical pain threshold, similar to UVB irradiation
[94]. Most importantly, the study showed that blockade of CXCL5
postirradiation, using a neutralizing antibody, reduces the
mechanical pain threshold, as well as the levels of the immune
response at the site [94]. Recently, a further investigative study
not only reproduced the data in the human skin, but also sug-
gested that fibroblasts might be involved in triggering the expres-
sion and secretion of CXCL5 at the skin, ultimately boosting UV
response [95]. Given these findings, a step forward toward the val-
idation of these targets is crucial, so they could meaningfully rep-
resent a plausible treatment for inflammatory hyperalgesia.
Other recent studies have identified unusual candidate mole-
cules that might be involved in UVB-inflammatory pain. One
group used the same principle of UVB inflammation but with the
intent of identifying lipid mediators [96]. By comparing tissue
from skin, DRG’s and spinal dorsal horn, the study identified
almost 20 different lipids isoforms that were upregulated upon
UVB irradiation, nearly all in peripheral tissues and almost none
at DRG and spinal cord levels [96]. Importantly, among this new
potential targets, five lipids (lipophosphatic acid 1:18 and 9; 13-S-
hydroxyoctadecadienoic acid; 5 and 12-hydroxyeicosatetraenoic
acid), which were recently identified as TRPV1 agonists [96–98],
were elevated in the skin of UVB rodents, suggesting that they
might contribute to thermal hyperalgesia and mechanical allody-
nia observed in inflammation [96].
Another study examined molecular changes after UVB irradia-
tion at the transcriptional level using RNA sequencing. By com-
paring skin samples of patients and rodents exposed to UVB, the
authors presented a remarkable level of similarity across the dif-
ferent species, identifying changes on over 800 common genes
[99]. Most of the changes in expression were found in the skin, as
previously reported [96]. Unsurprisingly, many of the genes
upregulated were related to inflammation [99]. The group also
looked at molecular changes at the DRGs and identified 39 genes
differentially regulated [99]. Interestingly, among the transcrip-
tional changes, VGF, a NGF-induced gene which has been impli-
cated in driving abnormal pain behavior [100–102], was identified
as one of the most upregulated genes [99]. These correlation anal-
ysis and in-depth molecular studies not only add an extra layer of
reassurance to the validation of the translational model for UVB,
but also provide new appealing targets with clinical relevance in
the pain field.
Conclusions
There is a considerable need to develop new classes of analgesic
drugs [103–105], and as a result, there have been many efforts
to bring new drugs to the clinic. Unfortunately, these efforts
have, to date, had only limited success in terms of new drug reg-
istrations. There have been some successes, particularly in the
last few years, with positive phase II trials in pain and related
sensory disturbances using anti-NGF, sodium channel blockers,
and Angiotensin II receptor and P2X3 receptor antagonists [105–
112]. One of the blocks to drug development in this area has
been translation from preclinical studies to humans. There are
probably multiple contributory factors, but one in particular has
been a concern over some of the models of persistent pain used
in the preclinical studies. We would like to propose here that
UV-induced sunburn may be a useful model to help in efforts to
understand inflammatory pain and develop new drugs. The
model produces a localized inflammatory response in an accessi-
ble tissue. It precipitates a reasonably well-defined series of sen-
sory changes, and particularly clear cut peripheral sensitization
of nociceptors, a process likely to be of considerable clinical rele-
vance in many pain states. Most importantly, the UVR model of
inflammation can be elicited both in humans and laboratory ani-
mals, apparently with consistent features in these species. This
last feature, which is not shared by many of the preclinical mod-
els used, allows for a much greater confidence in translation. As
the model can be induced easily in humans, it can also be used
in phase I studies and potentially provide an early indication of
efficacy.
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